Colon Carcinoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Colon Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions.
Colon carcinoma is a type of cancer that affects the large intestine, which includes the colon and the rectum. It is one of the most common cancers worldwide and can cause symptoms such as blood in the stool, weight loss, and fatigue. Colon carcinoma usually develops from benign growths called polyps that form on the inner lining of the colon or rectum. Some of these polyps can become malignant over time and invade the surrounding tissues or spread to other parts of the body. The risk factors for colon carcinoma include older age, diet, obesity, smoking, alcohol use, inflammatory bowel disease, and genetic disorders. Colon carcinoma can be diagnosed by biopsy during a colonoscopy or sigmoidoscopy, and treated by surgery, radiation therapy, chemotherapy, or targeted therapy depending on the stage and location of the tumor. Screening tests can help detect and remove polyps before they become cancerous and reduce the mortality from colon carcinoma.
The Colon Carcinoma drugs in development market research report provide comprehensive information on the therapeutics under development for Colon Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colon Carcinoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Colon Carcinoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 39 molecules, with 34 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Colon Carcinoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Colon Carcinoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Colon Carcinoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Actym Therapeutics IncAlligator Bioscience AB
Anwita Biosciences Inc
Avidin Biotechnology Ltd
Avidity Biosciences Inc
BioAtla Inc
Bordeaux Segalen University
Center for Genetic Engineering and Biotechnology
Changchun Huapu Biotechnology Co Ltd
Chinook Therapeutics Inc
Cytodyn Inc
eFFECTOR Therapeutics Inc
Emcure Pharmaceuticals Ltd
EnzymeBioSystems
Eucure (Beijing) Biopharma Co Ltd
GSK plc
Harbour BioMed (Guangzhou) Co Ltd
Innate Pharma SA
iOmx Therapeutics AG
iOnctura SA
JN Biosciences LLC
KAHR medical Ltd
Kansas State University
Kyung Hee University
MediciNova Inc
Mendus AB
Nektar Therapeutics
Omeros Corp
Phio Pharmaceuticals Corp
PolyPid Ltd
Qilu Puget Sound Biotherapeutics Corp
University of Minnesota
University of Oslo
Werewolf Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Colon Carcinoma reports